NVAX Novavax Inc

Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced that Stanley C. Erck, President and CEO, will present at the 27th Annual Piper Jaffray Healthcare Conference.

Conference details are as follows:

Date: Tuesday, December 1, 2015Time: 2:00 p.m. U.S. Eastern TimeLocation: New York Palace Hotel, New York CityLive webcast: http://edge.media-server.com/m/p/ui3ne8dn

The webcast and a replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company’s website, novavax.com.

Contact:

Novavax, Inc.

Barclay A. Phillips
SVP, Chief Financial Officer and Treasurer

Andrea N. Flynn, Ph.D.
Senior Manager, Investor Relations

ir@novavax.com
240-268-2000

Russo Partners, LLC

David Schull
Todd Davenport, Ph.D.

david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
212-845-4271